which glp 1 agonist is approved for weight loss Comparing Ozempic, Wegovy and Other GLP-1 Drugs What are GLP-1 Receptor Agonists?

This approach reflects the success seen with SGLT2 inhibitors, which have demonstrated significant cardioprotective and anti-inflammatory effects in conditions such as SLE, leading to their integration into clinical practice for autoimmune diseases (83)

In a cohort of 3731 patients, weight loss of 5%, 10%, and 15% was observed in 63%, 33%, and 14%, respectively, after 56 weeks of treatment (27%, 11%, and 4% with placebo),69 or of an additional 6% at 56 weeks in patients who had already lost 6% through hypocaloric diet and exercise.70 Positive results were also observed in adolescent patients with obesity,71 and in real-life studies substantial weight loss has also been reported.7275 Phase 3 trials with GLP-1 receptor agonists indicated specifically for obesity and overweight

Studies and regulatory findings include: In June 2025, the World Health Organization alerted healthcare professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide medications, including Ozempic, Rybelsus, and Wegovy

GLP-1 medications like semaglutide and tirzepatide have helped many patients lose weight, and they absolutely have a role in obesity treatment